BBHC
LCTX icon

Brown Brothers Harriman & Co’s Lineage Cell Therapeutics LCTX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3K Hold
9,379
– – ﹤0.01% 1388
2026
Q1 		$14.8K Buy
+9,379
New +$15.8K ﹤0.01% 1282

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Brown Brothers Harriman & Co's LCTX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 9,379 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1388.

Brown Brothers Harriman & Co first reported a position in LCTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $14.8K in Q1 2026. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Brown Brothers Harriman & Co held 9,379 shares of Lineage Cell Therapeutics worth $12.3K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1388 holding.
  • Brown Brothers Harriman & Co first reported a position in Lineage Cell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Brown Brothers Harriman & Co's Lineage Cell Therapeutics position peaked at $14.8K in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.